Oncobiologics (NASDAQ:OTLK) Upgraded at BTIG Research

BTIG Research upgraded shares of Oncobiologics (NASDAQ:OTLK) from a neutral rating to a buy rating in a report released on Monday, Marketbeat.com reports. They currently have $4.00 price objective on the stock.

A number of other analysts have also weighed in on the stock. Weiss Ratings upgraded shares of Oncobiologics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, June 24th. Ascendiant Capital Markets upped their target price on shares of Oncobiologics from $6.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, June 11th. Finally, Wall Street Zen cut shares of Oncobiologics from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $4.65.

Oncobiologics Trading Up 10.6%

Oncobiologics stock opened at $1.00 on Monday. Oncobiologics has a 12 month low of $0.16 and a 12 month high of $3.39. The company has a market capitalization of $148.59 million, a price-to-earnings ratio of -0.85 and a beta of 0.77. The business’s fifty day simple moving average is $1.22 and its two-hundred day simple moving average is $0.66.

Oncobiologics (NASDAQ:OTLK) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The firm had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $4.39 million. On average, equities research analysts predict that Oncobiologics will post -0.49 EPS for the current year.

Insiders Place Their Bets

In other Oncobiologics news, Director Faisal Ghiath Sukhtian acquired 95,398 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The shares were bought at an average cost of $1.05 per share, with a total value of $100,167.90. Following the completion of the transaction, the director directly owned 220,972 shares of the company’s stock, valued at approximately $232,020.60. This represents a 75.97% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ghiath M. Sukhtian acquired 8,539,709 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The shares were acquired at an average cost of $0.59 per share, for a total transaction of $5,038,428.31. Following the completion of the transaction, the director directly owned 22,092,068 shares of the company’s stock, valued at $13,034,320.12. The trade was a 63.01% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders have bought 8,664,107 shares of company stock worth $5,162,666. Corporate insiders own 1.80% of the company’s stock.

Institutional Trading of Oncobiologics

A number of institutional investors have recently made changes to their positions in OTLK. Russell Investments Group Ltd. increased its holdings in Oncobiologics by 865.2% during the second quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock valued at $39,000 after buying an additional 21,941 shares during the last quarter. AQR Capital Management LLC grew its position in shares of Oncobiologics by 42.7% during the 1st quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after acquiring an additional 25,351 shares during the period. Finally, Goldman Sachs Group Inc. grew its position in shares of Oncobiologics by 74.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock valued at $126,000 after acquiring an additional 44,063 shares during the period. Hedge funds and other institutional investors own 11.20% of the company’s stock.

Key Oncobiologics News

Here are the key news stories impacting Oncobiologics this week:

• Positive Sentiment: Director Faisal Ghiath Sukhtian bought 95,398 shares at an average price of $1.05, investing approximately $100,168. The purchase increased his direct ownership by nearly 76% to 220,972 shares, a potential signal of insider confidence. SEC insider transaction filing
• Positive Sentiment: BTIG Research upgraded OTLK to “Buy,” providing a stronger bullish view than the existing neutral coverage. BTIG Research upgrades Oncobiologics
• Positive Sentiment: HC Wainwright substantially improved its forecasts for 2027, raising full-year EPS expectations to a loss of $0.03 from a loss of $0.21. It also projects a return to profitability in 2028, with EPS of $0.09, followed by $0.15 in 2029 and $0.32 in 2030. The firm maintains a $1.60 price target.
• Neutral Sentiment: HC Wainwright raised estimates for several 2026–2027 quarters, but still rates OTLK “Neutral.” Its FY2026 EPS forecast was reduced to a loss of $0.47 from $0.42, indicating that near-term profitability remains uncertain.
• Negative Sentiment: A separate report on LYTENAVA—identified in the article as an Outlook Therapeutics program—cited significant cash constraints and the need for funding or a partnership before a U.S. launch. Although the therapy has FDA and European approval, competition in the anti-VEGF market could make commercialization difficult. Caution on LYTENAVA approval and cash needs

About Oncobiologics

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.